Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Sarepta Therapeutics Inc patents


Recent patent applications related to Sarepta Therapeutics Inc. Sarepta Therapeutics Inc is listed as an Agent/Assignee. Note: Sarepta Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with Sarepta Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "S" | Sarepta Therapeutics Inc-related inventors


Methods and compounds for treatment of lymphocyte-related diseases and conditions

Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein r1, l1, x, y and z are as defined herein.. ... Sarepta Therapeutics Inc

Compositions for treating muscular dystrophy

Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.. . ... Sarepta Therapeutics Inc

Oligonucleotide analogues targeting human lmna

Provided are lmna-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced lmna mrna isoforms that encode progerin.. . ... Sarepta Therapeutics Inc

Multiple exon skipping compositions for dmd

Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.. . ... Sarepta Therapeutics Inc

Exon skipping compositions for treating muscular dystrophy

Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.. . ... Sarepta Therapeutics Inc

Exon skipping compositions for treating muscular dystrophy

Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.. . ... Sarepta Therapeutics Inc

Exon skipping compositions for treating muscular dystrophy

Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.. . ... Sarepta Therapeutics Inc

Exon skipping compositions for treating muscular dystrophy

Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.. . ... Sarepta Therapeutics Inc

Antisense antiviral compounds and methods for treating a filovirus infection

The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the filoviridae family, including ebola and marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by ebola and marburg viruses. ... Sarepta Therapeutics Inc

Multiple exon skipping compositions for dmd

Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.. . ... Sarepta Therapeutics Inc

Compositions for treating muscular dystrophy

Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.. . ... Sarepta Therapeutics Inc

Antibacterial antisense oligonucleotide and method

A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3′ or 5′ end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological ph. ... Sarepta Therapeutics Inc

Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mrna splice products produces beneficial therapeutic effects.. ... Sarepta Therapeutics Inc

Splice-region antisense composition and method

Antisense compositions targeted against an mrna sequence coding for a selected protein, at a region having its 5′ end from 1 to about 25 base pairs downstream of a normal splice acceptor junction in the preprocessed mrna, are disclosed. The antisense compound is rnase-inactive, and is preferably a phosphorodiamidate-linked morpholino oligonucleotide. ... Sarepta Therapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Sarepta Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sarepta Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###